

Highlights of This Issue 567

REVIEW

- 569 | **Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment**
Enrique Grande, María-Victoria Bolós, and Eburne Arriola

THERAPEUTIC DISCOVERY

- 580 | **GPR54 Is a Target for Suppression of Metastasis in Endometrial Cancer**
Hyun Sook Kang, Tsukasa Baba, Masaki Mandai, Noriomi Matsumura, Junzo Hamanishi, Budiman Kharma, Eiji Kondoh, Yumiko Yoshioka, Shinya Oishi, Nobutaka Fujii, Susan K. Murphy, and Ikuo Konishi

- 591 | **Targeting the Replication Checkpoint Using SCH 900776, a Potent and Functionally Selective CHK1 Inhibitor Identified via High Content Screening**
Timothy J. Guzi, Kamil Paruch, Michael P. Dwyer, Marc Labroli, Frances Shanahan, Nicole Davis, Lorena Taricani, Derek Wiswell, Wolfgang Seghezzi, Ervin Penaflo, Bhagyashree Bhagwat, Wei Wang, Danling Gu, Yunsheng Hsieh, Suining Lee, Ming Liu, and David Parry

- 603 | **Targeted Delivery of an Antibody-Mutant Human Endostatin Fusion Protein Results in Enhanced Antitumor Efficacy**
Seung-Uon Shin, Hyun-Mi Cho, Jaime Merchan, Jin Zhang, Krisztina Kovacs, Yawu Jing, Sundaram Ramakrishnan, and Joseph D. Rosenblatt

- 615 | **Novel Functions for *mda-7/IL-24* and *IL-24* *deIE5*: Regulation of Differentiation of Acute Myeloid Leukemic Cells**
Bin-Xia Yang, Yong-Juan Duan, Cheng-Ya Dong, Fang Zhang, Wei-Feng Gao, Xue-Ying Cui, Yong-Min Lin, and Xiao-Tong Ma

- 626 | **Targeting Ovarian Tumor Cell Adhesion Mediated by Tissue Transglutaminase**
May Khanna, Bhadrani Chelladurai, Aruna Gavini, Liwei Li, Minghai Shao, David Courtney, John J. Turchi, Daniela Matei, and Samy Meroueh

- 637 | **Cancer-Targeted BikDD Gene Therapy Elicits Protective Antitumor Immunity against Lung Cancer**
Yuh-Pyng Sher, Shih-Jen Liu, Chun-Mien Chang, Shu-Pei Lien, Chien-Hua Chen, Zhenbo Han, Long-Yuan Li, Jin-Shing Chen, Cheng-Wen Wu, and Mien-Chie Hung

- 648 | **Enigmol: A Novel Sphingolipid Analogue with Anticancer Activity against Cancer Cell Lines and *In vivo* Models for Intestinal and Prostate Cancer**
Holly Symolon, Anatoliy Bushnev, Qiong Peng, Harsha Ramaraju, Suzanne G. Mays, Jeremy C. Allegood, Sarah T. Prueett, M. Cameron Sullards, Dirck L. Dillehay, Dennis C. Liotta, and Alfred H. Merrill, Jr.

- 658 | **Radiosensitization of Head and Neck Squamous Cell Carcinoma by a SMAC-Mimetic Compound, SM-164, Requires Activation of Caspases**
Jie Yang, Donna McEachern, Wenyan Li, Mary A. Davis, Hua Li, Meredith A. Morgan, Longchuan Bai, Jonathan T. Sebolt, Haiying Sun, Theodore S. Lawrence, Shaomeng Wang, and Yi Sun

PRECLINICAL DEVELOPMENT

- 670 | **Context Dependence of Checkpoint Kinase 1 as a Therapeutic Target for Pancreatic Cancers Deficient in the BRCA2 Tumor Suppressor**
Hiroyoshi Hattori, Ferdinandos Skoulidis, Paul Russell, and Ashok R. Venkiteswaran

- 679 | **Rapamycin Reverses Splenomegaly and Inhibits Tumor Development in a Transgenic Model of Epstein-Barr Virus-Related Burkitt's Lymphoma**
Osman Cen and Richard Longnecker

MOLECULAR MEDICINE IN PRACTICE

687 | **Gene Expression Profiling Provides Insights into Pathways of Oxaliplatin-Related Sinusoidal Obstruction Syndrome in Humans**

Laura Rubbia-Brandt, Sébastien Tauzin, Catherine Brezault, Céline Delucinge-Vivier, Patrick Descombes, Bertand Dousset, Pietro E. Majno, Gilles Mentha, and Benoit Terris

697 | **Evasion Mechanisms to Igf1r Inhibition in Rhabdomyosarcoma**

Jinu Abraham, Suresh I. Prajapati, Koichi Nishijo, Beverly S. Schaffer, Eri Taniguchi, Aoife Kilcoyne, Amanda T. McCleish, Laura D. Nelon, Francis G. Giles, Argiris Efstratiadis, Robin D. LeGallo, Brent M. Nowak, Brian P. Rubin, Suman Malempati, Charles Keller

CORRECTION

708 | **Correction: Interstitial Infusion of Glioma-Targeted Recombinant Immunotoxin 8H9scFv-PE38**

ABOUT THE COVER

Genetically-engineered mouse models often represent some of the most physiologically accurate models of cancer from which to understand the tumor microenvironment and with which to perform preclinical trials. Abraham and colleagues present studies of a prototypic insulin-like growth factor receptor inhibitor using both genetically-engineered mouse models and the shell-free quail chorioallantois membrane (CAM) assay. Remarkably, the inexpensive short term (2 week) CAM assay offers xenografted tumors a scaffold of lymphatics, arteries, and veins that mimic short-term *in vivo* growth with all the advantages of intravital imaging. Photograph credits, Elaine Huang and Audra Lee. For details, see article by Abraham and colleagues on page 697.



Molecular Cancer Therapeutics

10 (4)

Mol Cancer Ther 2011;10:567-708.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/10/4>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://mct.aacrjournals.org/content/10/4>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.